Calypso Biotech
Translating IL-15 biology into medical breakthroughs
Calypso Biotech BV is a spin-off of the healthcare business of Merck KGaA, Darmstadt, Germany and develops novel biologics to address unmet medical needs in autoimmune and inflammatory diseases, with unique expertise in IL-15 biology. IL-15 controls immune pathways critically involved in disease onset, maintenance and tissue destruction and has a broad effect on inflammation. Calypso’s approach could provide for unprecedented long-lasting disease-modifying effects in autoimmune diseases. Its best-in-class anti-IL-15 monoclonal antibody is currently in Phase I clinical trials for Refractory Celiac Disease and orphan indication Eosinophilic Esophagitis, with additional indications being explored preclinically.
Calypso is backed by investors M Ventures, JJDC, Gilde Healthcare, INKEF and Fountain Healthcare Partners and is headquartered in Amsterdam, The Netherlands, with offices and labs in Geneva, Switzerland.